Claims
- 1. A purified carotenoid concentrate comprising mixed zeaxanthin C8-C20 carboxylic acid esters in which the mixed zeaxanthin esters constitute about 50 mg/g or more of the concentrate and wherein the zeaxanthin is about 20 percent or more of the total carotenoids present when assayed after saponification.
- 2. The carotenoid concentrate according to claim 1 wherein said zeaxanthin esters are monoesterified zeaxanthin, diesterified zeaxanthin or mixtures thereof.
- 3. The carotenoid concentrate according to claim 1 wherein the acid portion of the mixed zeaxanthin esters comprises a plurality of acids selected from the group consisting of palmitic, stearic, myristic, oleic, linoleic, linolenic, lauric, palmitoleic, pentadecanoic, and capric acids.
- 4. The carotenoid concentrate according to claim 1 wherein said zeaxanthin is about 25 percent or more of the total carotenoids present when assayed after saponification.
- 5. The carotenoid concentrate according to claim 1 wherein said total carotenoids include at least one additional carotenoid in free or esterified form.
- 6. The carotenoid concentrate according to claim 5 wherein said additional carotenoid is selected from the group consisting of a carotene, a xanthophyll, a monoesterified xanthophyll, a diesterified xanthophyll and mixtures thereof.
- 7. The carotenoid concentrate according to claim 1 wherein said mixed zeaxanthin esters are extracted from a plant of the family Compositae.
- 8. The carotenoid concentrate according to claim 7 wherein said mixed zeaxanthin esters are extracted from the species Tagetes erecta.
- 9. A diluted purified carotenoid composition comprising mixed zeaxanthin C8-C20 carboxylic acid esters dissolved or dispersed in a comestible diluent in which the mixed zeaxanthin esters constitute about 10 mg/g or more of the diluted composition and wherein the zeaxanthin is about 20 percent or more of the total carotenoids present when assayed after saponification.
- 10. The carotenoid composition according to claim 9 wherein said comestible diluent is an oil.
- 11. The carotenoid composition according to claim 9 wherein said composition is present encapsulated within a beadlet.
- 12. The carotenoid composition according to claim 9 wherein said zeaxanthin esters are monoesterified zeaxanthin, diesterified zeaxanthin or mixtures thereof.
- 13. The carotenoid composition according to claim 9 wherein the acid portion of the mixed zeaxanthin esters comprises a plurality of acids selected from the group consisting of palmitic, stearic, myristic, oleic, linoleic, linolenic, lauric, palmitoleic, pentadecanoic, and capric acids.
- 14. The carotenoid composition according to claim 9 wherein said zeaxanthin is about 25 percent or more of the total carotenoids present when assayed after saponification.
- 15. The carotenoid composition according to claim 9 wherein said total carotenoids include at least one additional carotenoid in free or esterified form.
- 16. The carotenoid composition according to claim 15 wherein said additional carotenoid is selected from the group consisting of a carotene, a xanthophyll, a monoesterified xanthophyll, a diesterified xanthophyll and mixtures thereof.
- 17. The carotenoid composition according to claim 9 wherein said mixed zeaxanthin esters are extracted from a plant of the family Compositae.
- 18. The carotenoid composition according to claim 9 wherein said mixed zeaxanthin esters are extracted from the species Tagetes erecta.
- 19. A composition suitable for oral administration that contains mixed zeaxanthin esters dissolved or dispersed in a comestible diluent and present in a nutritionally effective amount in a unit dosage form.
- 20. The composition according to claim 19 wherein said unit dosage form comprises a particulate formulation.
- 21. The composition according to claim 19 wherein said nutritionally effective amount is an amount sufficient to treat or prevent macular degeneration or cataract formation.
- 22. The composition according to claim 19 wherein said nutritionally effective amount is an amount sufficient to prevent cancer.
- 23. The composition according to claim 19 wherein said nutritionally effective amount is an amount sufficient to treat or prevent free radical-mediated diseases.
- 24. The composition according to claim 23 wherein said free radical mediated-diseases are selected from the group consisting of inflammatory-immune injury, alcohol damage, radiation injury, premature aging disorders, age-related immunodeficiency, cancer, rheumatoid arthritis, atherosclerosis, senile dementia, Alzheimer's disease, Parkinson's disease (MPTP), muscular sclerosis, cataractogenisis, degenerative retinal damage, and solar radiation.
- 25. The composition according to claim 19 wherein said nutritionally effective amount is about 2 milligrams or more.
- 26. A food substance or beverage suitable for mammalian consumption that contains an additive of mixed zeaxanthin esters dissolved or dispersed in a comestible diluent and present in a nutritionally effective amount.
- 27. The food substance or beverage according to claim 26 wherein said nutritionally effective amount is about 0.5 milligram to about 8 milligrams per serving.
- 28. The food substance or beverage according to claim 26 wherein said food substance a pet food.
- 29. The food substance or beverage according to claim 26 wherein said food substance a medical food.
- 30. The medical food according to claim 29 wherein said nutritionally effective amount is an amount sufficient to treat or prevent macular degeneration or cataract formation.
- 31. The medical food according to claim 29 wherein said nutritionally effective amount is an amount sufficient to prevent cancer.
- 32. The medical food according to claim 29 wherein said nutritionally effective amount is an amount sufficient to prevent free radical-mediated diseases.
- 33. The medical food according to claim 32 wherein said free radical mediated-diseases are selected from the group consisting of inflammatory-immune injury, alcohol damage, radiation injury, premature aging disorders, age-related immunodeficiency, cancer, rheumatoid arthritis, atherosclerosis, senile dementia, Alzheimer's disease, Parkinson's disease (MPTP), muscular sclerosis, cataractogenisis, degenerative retinal damage, and solar radiation.
- 34. The medical food according to claim 29 wherein the nutritionally effective amount is sufficient to provide up to about 40 mg per day in a single or in multiple administrations.
- 35. A diluted purified carotenoid composition comprising mixed zeaxanthin C8-C20 carboxylic acid esters dissolved or dispersed in a cosmetically acceptable diluent in which the mixed zeaxanthin esters constitute about 10 mg/g or more of the diluted composition and wherein the zeaxanthin is about 20 percent or more of the total carotenoids present when assayed after saponification.
- 36. The carotenoid composition according to claim 35 wherein said zeaxanthin esters are monoesterified zeaxanthin, diesterified zeaxanthin or mixtures thereof.
- 37. The carotenoid composition according to claim 35 wherein the acid portion of the mixed zeaxanthin esters comprises a plurality of acids selected from the group consisting of palmitic, stearic, myristic, oleic, linoleic, linolenic, lauric, palmitoleic, pentadecanoic, and capric acids.
- 38. The carotenoid composition according to claim 35 wherein said zeaxanthin is about 25 percent or more of the total carotenoids present when assayed after saponification.
- 39. The carotenoid composition according to claim 35 wherein said total carotenoids include at least one additional carotenoid in free or esterified form.
- 40. The carotenoid composition according to claim 39 wherein said additional carotenoid is selected from the group consisting of a carotene, a xanthophyll, a monoesterified xanthophyll, a diesterified xanthophyll and mixtures thereof.
- 41. The carotenoid composition according to claim 35 wherein said mixed zeaxanthin esters are extracted from a plant of the family Compositae.
- 42. The carotenoid composition according to claim 41 wherein said mixed zeaxanthin esters are extracted from the species Tagetes erecta.
- 43. A topical cream, lotion, or ointment that contains mixed zeaxanthin esters dissolved or dispersed in a diluent and present in a light protection effective amount.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation-in-part of application Ser. No. 10/325,265 filed on Dec. 19, 2002 entitled “Tagetes erecta MARIGOLDS WITH ALTERED CAROTENOID COMPOSITIONS AND RATIOS” that is a continuation-in-part of application Ser. No. 10/180,775 that was filed on Jun. 26, 2002, that claimed priority from provisional application Serial No. 60/302,460 that was filed on Jun. 29, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60302460 |
Jun 2001 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10325265 |
Dec 2002 |
US |
Child |
10453403 |
Jun 2003 |
US |
Parent |
10180775 |
Jun 2002 |
US |
Child |
10325265 |
Dec 2002 |
US |